Nosten 1994 THA.

Methods	Trial design: RCT Data collected: 1987 to 1990 Length of follow‐up: from first antenatal visit at > 20 weeks of estimated gestation to 2 years after delivery Frequency of follow‐up: weekly
Participants	Parity: all Number: 339 Inclusion criteria: antenatal attendees > 20 weeks of gestation Excluded: none stated
Interventions	Mefloquine: weekly Nothing Other: treated antenatally if parasitaemic; given folic acid and iron if anaemic Administration supervised: yes
Outcomes	Antenatal episodes of parasitaemia Anaemia Preterm birth Birthweight Perinatal death
Notes	Location: Thailand Urban/rural: rural (camps Wangka, Shoklo, Bonoko) Malaria transmission: unstable malarious area (mesoendemic) Drug resistance: multiple drug resistance present Funding: United Nations Development Programme/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Wellcome Trust of Great Britain; Prevention Foundation, The Hague
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Trial described as "a double‐blind, placebo‐controlled trial". No details provided of the sequence generation method used.
Allocation concealment (selection bias)	Unclear risk	No details provided.
Blinding (performance bias and detection bias) All outcomes	Low risk	Placebo tablets identical with treatments were used. "The investigators were unaware of the randomization".
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Blinding of outcome assessors not mentioned.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rate 8% (10/119) in Phase 1 and 8% (18/220) in Phase 2. Across groups: 7.1% (12/170) were excluded from the mefloquine group and 9.5% (16/169) were excluded from the placebo group. Explanation provided.
Selective reporting (reporting bias)	Low risk	No apparent risk.
Other bias	Low risk	None identified.